BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 193.4 SEK | -0.10% |
|
-2.81% | -27.78% |
| Apr. 22 | Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest | DJ |
| Apr. 20 | BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 502M 46.34M | Sales 2025 * | 1.01B 93.17M | Capitalization | 17.1B 1.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.48M | Net income 2025 * | 454M 41.87M | EV / Sales 2024 * | 32.4 x |
| Net cash position 2024 * | 838M 77.25M | Net cash position 2025 * | 1.17B 108M | EV / Sales 2025 * | 15.8 x |
| P/E ratio 2024 * |
973
x | P/E ratio 2025 * |
37.7
x | Employees | 88 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioArctic AB
More press releases
More news
| 1 day | -1.08% | ||
| 1 week | -3.82% | ||
| Current month | -1.85% | ||
| 1 month | -7.98% | ||
| 3 months | -9.55% | ||
| 6 months | -14.55% | ||
| Current year | -28.53% |
1 week
191.00
199.00
1 month
175.00235.80
Current year
175.00288.40
1 year
175.00392.00
3 years
66.70392.00
5 years
47.00392.00
10 years
20.40392.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 12-12-31 | |
| Founder | 77 | 03-01-23 | |
| Founder | 75 | 03-01-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eugen Steiner
CHM | Chairman | 70 | 16-12-31 |
| Director/Board Member | 58 | 23-05-31 | |
| Director/Board Member | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.25% | 5 M€ | +9.66% | ||
| 0.89% | 16 M€ | -4.13% | ||
| 0.25% | 148 M€ | +9.14% | - | |
| 0.19% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 193.4 | -0.10% | 43 739 |
| 24-05-03 | 193.6 | -0.72% | 55,278 |
| 24-05-02 | 195 | 0.00% | 90,495 |
| 24-04-30 | 195 | -2.01% | 46,386 |
| 24-04-29 | 199 | +0.76% | 109,223 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 04:24 am EDT
More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
2024-05-17
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
193.6
SEK
Average target price
366.2
SEK
Spread / Average Target
+89.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.53% | 1.58B | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- BIOA B Stock